http://informahealthcare.com/doi/abs/10.3109/15622975.2013.765593
Objectives. The treatment of major affective disorders,
commonly associated with high disability and elevated social costs may
be still considered unsatisfactory. Among all antidepressant drugs,
predominantly acting through monoaminergic mechanisms, agomelatine is of
particular interest due to another alternative mechanism of action.
Targeting melatonergic receptors, agomelatine play a crucial role in
synchronizing circadian rhythms, known to be altered in depressed
subjects. Methods. A critical review of the literature focusing
on efficacy, safety and tolerability of agomelatine in major affective
disorders was performed. Additionally, we focused on the potential of
agomelatine in enhancing neuroplasticity mechanisms and promote
neurogenesis. A total of 136 articles from peer-reviewed journals were
identified, of which 50 were assessed for eligibility and 21 were
included. Results. Agomelatine, a melatonergic analogue drug acting as MT1/MT2 agonist and 5-HT2C
antagonist, has been reported to be effective as antidepressant drug.
Studies confirmed not only clinical efficacy but also safety and
tolerability of agomelatine. Also, it enhances neuroplasticity
mechanisms and adult neurogenesis in brain areas such as hippocampus and
prefrontal cortex. Conclusions. Agomelatine actually represents an intriguing option in the treatment of affective disorders.
No comments:
Post a Comment